Expanding anti-CD38 immunotherapy for lymphoid malignancies

Expanding anti-CD38 immunotherapy for lymphoid malignancies

Abstract Background Lymphoid neoplasms, including multiple myeloma (MM), non-Hodgkin lymphoma (NHL), and NK/T cell neoplasms, are a major cause of blood cancer morbidity and mortality. CD38 (cyclic ADP ribose hydrolase) is a transmembrane glycoprotein expressed on the surface of plasma cells and MM...

Full description

Bibliographic Details
Main Authors: Xu Wang, Xinfang Yu, Wei Li, Praveen Neeli, Ming Liu, Ling Li, Mingzhi Zhang, Xiaosheng Fang, Ken H. Young, Yong Li
Format: Article
Language:English
Published: BMC 2022-06-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
Multiple myeloma
Non-Hodgkin lymphoma
CD38
CAR T
Daratumumab
All-trans retinoic acid
Online Access:https://doi.org/10.1186/s13046-022-02421-2

Internet

https://doi.org/10.1186/s13046-022-02421-2

Similar Items